Daidzein Derivative Daid 002 Inhibits Glioblastoma Growth Via Disrupting the Interaction Between Moesin and CD 44

Xin Zhang,Xiuting Liu,Jinghui Zhang,Wei Zhou,Jinrong Lu,Qing Wang,Rong Hu
DOI: https://doi.org/10.18632/oncotarget.24166
2018-01-01
Oncotarget
Abstract:Glioblastoma multiforme is a fatal brain tumor with very limited therapeutic options. Recently, an ezrin-radixin-moesin family protein, moesin, is reported to be positively correlated with higher grade of glioblastoma. Here, we reported that daid002, a novel daidzein derivative, inhibited glioblastoma growth and induced G0/ G1 phase arrest. Daid002 decreased moesin phosphorylation through restraint of the direct interaction between moesin and CD44 on the cell membrane and reduced cyclin D1 expression via regulating nuclear translocation of β-catenin. In vivo, daid002 exerted a significant inhibition on glioblastoma growth through CD44/moesin signaling. Our findings established daid002 as an anti-glioblastoma agent by targeting CD44/moesin.
What problem does this paper attempt to address?